Literature DB >> 1828713

Location of P-II and AlPCS4 in human tumor LOX in vitro and in vivo by means of computer-enhanced video fluorescence microscopy.

Q Peng1, J Moan, G W Farrants, H E Danielsen, C Rimington.   

Abstract

The patterns of in vitro intracellular and in vivo intratumoral localization of Photofrin II (P-II) and aluminum phthalocyanine tetrasulfonate (AlPCS4) in human melanoma LOX were studied by means of computer-enhanced video fluorescence microscopy (CEVFM). The hydrophobic drug P-II localized diffusely in the perinuclear fraction of the cytoplasm of the LOX cells cultivated in vitro. Light exposure did not result in any observable change in the localization pattern. The hydrophilic dye AlPCS4 was distributed as granular and grain patterns in the cytoplasm before light exposure, in exactly the same pattern as that of acridine orange incubated in the same cells, which is known to emit red fluorescence from lysosomes, thus indicating that AlPCS4 was also primarily localized in the lysosomes of the LOX cells. After light exposure the distribution of the intracellular AlPCS4 fluorescence was altered and the intensity increased. In vivo, P-II had a combined cellular localization pattern (i.e. a strongly cytoplasmic membrane-localizing pattern and a weakly intracellular distribution pattern) and an extracellular distribution pattern in the tumor tissue, while the AlPCS4 fluorescence was seen mainly in the stroma of the tumor. The total fluorescence intensity of P-II and AlPCS4 in the LOX tumor tissue at different times after injection was quantitatively determined by means of CEVFM.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828713     DOI: 10.1016/0304-3835(91)90021-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

Review 1.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  AlPcS4-PDT for gastric cancer therapy using gold nanorod, cationic liposome, and Pluronic® F127 nanomicellar drug carriers.

Authors:  Jing Xin; Sijia Wang; Bing Wang; Jiazhuang Wang; Jing Wang; Luwei Zhang; Bo Xin; Lijian Shen; Zhenxi Zhang; Cuiping Yao
Journal:  Int J Nanomedicine       Date:  2018-04-04

3.  Comparison of the synergistic anticancer activity of AlPcS4 photodynamic therapy in combination with different low‑dose chemotherapeutic agents on gastric cancer cells.

Authors:  Jing Xin; Senhao Wang; Luwei Zhang; Bo Xin; Yulu He; Jing Wang; Sijia Wang; Lijian Shen; Zhenxi Zhang; Cuiping Yao
Journal:  Oncol Rep       Date:  2018-05-16       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.